Biotechnology Startup Funding 2025-2026

In our biotechnology market deck, you will find everything you need to understand the market
SUMMARY
This report analyzes publicly disclosed equity financings identified for pure-play biotechnology companies from August 2025 through September 2, 2026, using a $300K minimum threshold and the biotechnology definition set out below. Because systematic public trackers disproportionately cover large rounds, the clean statistical sample contains 77 exact, period-specific financings totaling approximately $11.75B rather than an exhaustive census of every $300K+ biotechnology deal.
The biotechnology funding market is extraordinarily capital intensive within this verified sample. The 77 clean financings were raised by 75 unique companies, with only Crystalys Therapeutics and Ollin Biosciences appearing twice in the exact-number dataset.
Capital is concentrated, but not entirely dependent on one company. Isomorphic Labs' $2.1B Series B represents 17.9% of verified capital, while the top 3 rounds account for 26.7%, the top 5 for 32.6%, and the top 10 for 44.3%.
The median disclosed financing in the verified sample is $101M and the average is approximately $153M. Those numbers describe the large-round sample, not the typical biotechnology financing across the full $300K+ market.
Therapeutics Discovery Platforms overwhelmingly dominate the observed dataset. They account for 69 of 77 clean financings and approximately $10.69B of the $11.75B captured, while Gene Editing Companies and Cell Therapy Developers together contribute only eight clean deals.
North America is the largest biotechnology fundraising geography in the verified sample, with 58 deals and approximately $7.44B. Europe contributes 14 deals and $3.72B, helped disproportionately by Isomorphic Labs' $2.1B financing.
Series B is the largest stage by capital in the sample, with 27 financings totaling approximately $5.51B. Series A is more frequent than conventional early-stage check sizes might suggest, with 23 rounds totaling $2.40B.
The visible biotechnology market is dominated by scaled financings. None of the 77 clean transactions is below $50M because the systematic source base used for this pass is optimized toward larger rounds, making small-round distribution statistics structurally unreliable.
Follow-on funding is a major feature of the observed market. Many of the largest financings back companies that have already demonstrated clinical progress, platform validation, asset selection, or an ability to raise institutional capital previously.
Investor repetition is substantial among specialist life-science funds and pharmaceutical strategics. RA Capital, OrbiMed, Sofinnova, Novo Holdings, Janus Henderson, Sanofi Ventures, Alexandria Venture Investments and other large specialists recur across different modalities rather than concentrating on only one biotechnology thesis.

This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
What are all the funding deals in the biotechnology market from August 2025 to September 2026?
The table below lists the clean, exact-value equity financings identified in the verified biotechnology dataset between August 2025 and September 2, 2026. We define the biotechnology market as products and services that apply modern biological science and engineering to create or improve medical and life-science outcomes, including biopharma R&D and therapeutics, molecular diagnostics, and core life-science research tools and reagents.
The dataset excludes routine healthcare delivery, conventional pharmaceuticals and chemicals not enabled by biotechnology, and agriculture or industrial bioapplications unless explicitly in scope. Because the systematic source base is strongest for large financings, this table should be read as a verified large-round dataset rather than an exhaustive global census down to $300K. For a wider view of the industry, see our Biotechnology market report.
| Company | What they do | Category | Date | Stage | Deal size | Region | Main investors |
|---|---|---|---|---|---|---|---|
| Strand Therapeutics | Programmable mRNA therapeutics designed to express therapeutic proteins selectively in target tissue | Therapeutics Discovery Platforms | Aug 2025 | Series B | $153M | North America | Kinnevik; Regeneron Ventures; ICONIQ; Amgen Ventures; Eli Lilly; others |
| Minghui Pharmaceutical | Biotechnology-derived immunology and oncology therapies including bispecific antibodies and ADCs | Therapeutics Discovery Platforms | Aug 2025 | Growth Equity | $131M | Asia-Pacific | OrbiMed; Qiming Venture Partners; TF Capital; BioTrack Capital; 5Y Capital; others |
| Kriya Therapeutics | Genetic medicines and gene therapies across multiple diseases | Gene Editing Companies | Aug 2025 | Unknown | $313M | North America | Financing disclosed through SEC filing |
| Arnatar Therapeutics | RNA medicines including an antisense oligonucleotide treatment for Alagille syndrome | Therapeutics Discovery Platforms | Aug 2025 | Series A | $52M | Asia-Pacific | Eight Roads; 3E Bioventures; F-Prime Capital; others |
| Wugen | Allogeneic off-the-shelf CAR-T therapies including WU-CART-007 | Cell Therapy Developers | Aug 2025 | Unknown | $115M | North America | Fidelity; RiverVest; Lightchain; Abingworth; ICG; Tybourne; Aisling |
| Plexium | Targeted protein-degradation therapeutics including molecular glues | Therapeutics Discovery Platforms | Aug 2025 | Unknown | $60.1M | North America | Not detailed in source summary |
| CHARM Therapeutics | AI-enabled structure-based drug discovery and AI-designed oncology therapeutics | Therapeutics Discovery Platforms | Sep 2025 | Series B | $80M | Europe | NEA; SR One; OrbiMed; F-Prime; Khosla Ventures; NVIDIA |
| Corsera Health | Long-duration RNAi medicines for cardiovascular disease and associated precision-development technology | Therapeutics Discovery Platforms | Sep 2025 | Unknown | $50M | North America | Clive Meanwell; John Maraganore; other investors |
| AllRock Bio | Biotechnology-derived ROCK inhibition therapies for pulmonary hypertension | Therapeutics Discovery Platforms | Sep 2025 | Series A | $50M | North America | Versant Ventures; Westlake BioPartners |
| Dualitas Therapeutics | Next-generation bispecific antibodies for allergic and autoimmune diseases | Therapeutics Discovery Platforms | Sep 2025 | Series A | $65M | North America | Versant Ventures; Qiming Venture Partners USA; SV Health Investors; Chugai; Eli Lilly; Alexandria |
| Ollin Biosciences | Ophthalmology biotechnology company developing bispecific antibodies | Therapeutics Discovery Platforms | Sep 2025 | Unknown | $100M | North America | ARCH Venture Partners; Mubadala Capital; Monograph Capital |
| Avenzo Therapeutics | Precision-oncology therapeutics including kinase inhibitors and antibody-drug conjugates | Therapeutics Discovery Platforms | Sep 2025 | Series B | $60M | North America | OrbiMed; SR One; Longwood; Foresite; Lilly Asia Ventures; NEA; others |
| Sparrow Therapeutics | Endocrine and metabolic therapeutics based on HSD-1 inhibition | Therapeutics Discovery Platforms | Sep 2025 | Series B | $95M | North America | RA Capital; Forbion; OrbiMed; RiverVest; US Venture Partners |
| Star Therapeutics | Biologic medicines for bleeding disorders including VGA039 | Therapeutics Discovery Platforms | Sep 2025 | Series D+ | $125M | North America | Sanofi Ventures; Viking Global; Sofinnova; Blue Owl; RA Capital; Janus Henderson; others |
| Crystalys Therapeutics | Develops dotinurad for gout and hyperuricemia through global registration-directed development | Therapeutics Discovery Platforms | Sep 2025 | Series A | $205M | North America | Novo Holdings; Catalys Pacific; SR One; Lightstone; Longwood; Alexandria |
| Nilo Therapeutics | Therapies targeting brain-body neural circuits that regulate immune function | Therapeutics Discovery Platforms | Oct 2025 | Series A | $101M | North America | The Column Group; DCVC Bio; Lux Capital; Gates Foundation; Alexandria |
| Arthrosi Therapeutics | Gout therapeutics including pozdeutinurad | Therapeutics Discovery Platforms | Oct 2025 | Series D+ | $153M | North America | Prime Eight Capital; CR Biotech; HighLight Capital; HM Venture Partners; ReliantTech; others |
| Expedition Therapeutics | DPP1 inhibition therapies for inflammatory respiratory diseases | Therapeutics Discovery Platforms | Oct 2025 | Series A | $165M | North America | Sofinnova Investments; Novo Holdings; Forbion; KKR; Adage; Sanofi Ventures; Venrock; others |
| Excellergy | Effector-cell response inhibitors for allergic disease | Therapeutics Discovery Platforms | Oct 2025 | Series A | $70M | North America | Samsara BioCapital; Red Tree Venture Capital; Decheng Capital |
| Kailera Therapeutics | Obesity and metabolic-disease medicines | Therapeutics Discovery Platforms | Oct 2025 | Series B | $600M | North America | Bain Capital Private Equity; Adage; CPP Investments; Invus; Janus Henderson; QIA; RTW; others |
| Pelage Pharmaceuticals | Regenerative medicines designed to reactivate hair-follicle stem cells | Therapeutics Discovery Platforms | Oct 2025 | Series B | $120M | North America | ARCH Venture Partners; GV; Main Street Advisors; Visionary Ventures; YK Bioventures |
| Tubulis | Next-generation antibody-drug-conjugate technology and therapeutics | Therapeutics Discovery Platforms | Oct 2025 | Series C | $361M | Europe | Venrock Healthcare; Wellington; Ascenta; Nextech; EQT Life Sciences; Frazier; Andera; others |
| Peptilogics | Computationally designed peptide therapeutics including treatments for severe infections | Therapeutics Discovery Platforms | Oct 2025 | Series B | $78M | North America | Presight Capital; Thiel Bio; Founders Fund; AMR Action Fund; Narya; Beyond Ventures |
| Adcytherix | Antibody-drug conjugate therapeutics | Therapeutics Discovery Platforms | Oct 2025 | Series A | $122M | Europe | Bpifrance; Kurma Partners; Andera Partners; Angelini Ventures; Surveyor Capital; aMoon |
| Elevara Medicines | Biotechnology-enabled therapeutics for immune diseases | Therapeutics Discovery Platforms | Oct 2025 | Series A | $70M | Europe | Forbion; Sofinnova Partners; Weatherden; Monograph Capital |
| Electra Therapeutics | Biologics designed to selectively eliminate pathological immune cells | Therapeutics Discovery Platforms | Oct 2025 | Series C | $183M | North America | Nextech; EQT Life Sciences; Sanofi; HBM; Mubadala; OrbiMed; Redmile; RA Capital; others |
| Hemab Therapeutics | Antibody therapeutics for rare bleeding disorders | Therapeutics Discovery Platforms | Oct 2025 | Series C | $157M | Europe | Sofinnova; Avoro; RA Capital; Novo Holdings; Access Biotechnology; Deep Track; others |
| AAVantgarde Bio | AAV gene therapies for inherited retinal diseases | Gene Editing Companies | Nov 2025 | Series B | $141M | Europe | Schroders Capital; Atlas Venture; Forbion; Amgen Ventures; CDP Venture Capital; Sofinnova; others |
| Solve Therapeutics | ADC therapeutics and proprietary linker technology | Therapeutics Discovery Platforms | Nov 2025 | Unknown | $120M | North America | Yosemite; Abingworth; Ally Bridge; B Capital; Balyasny; Merck; SymBiosis; Alexandria; others |
| Profluent | AI protein design and programmable biology for gene-editing systems | Gene Editing Companies | Nov 2025 | Unknown | $106M | North America | Altimeter; Bezos Expeditions; Spark Capital; Insight Partners; Air Street Capital |
| Aspen Neuroscience | Autologous iPSC-derived neuronal replacement therapies | Cell Therapy Developers | Nov 2025 | Series C | $115M | North America | OrbiMed; ARCH; Frazier; Revelation; Medical Excellence Capital; S32; Kite; others |
| Protego Biopharma | Disease-modifying protein-stabilization therapeutics for amyloidosis | Therapeutics Discovery Platforms | Dec 2025 | Series B | $130M | North America | Novartis Venture Fund; Forbion; Omega; Droia; Vida; MPM BioImpact; Lightspeed; others |
| Link Cell Therapies | CAR-T cell therapies for solid tumors | Cell Therapy Developers | Dec 2025 | Series A | $60M | North America | Samsara BioCapital; Sheatree; JJDC; Bristol Myers Squibb; Kyowa Kirin; Wing; Sherpa |
| Chai Discovery | AI models used to design antibodies and other therapeutic molecules | Therapeutics Discovery Platforms | Dec 2025 | Series B | $130M | North America | Oak HC/FT; General Catalyst; Thrive; OpenAI; Dimension; Menlo; others |
| Ambros Therapeutics | Late-stage rare-disease therapeutics | Therapeutics Discovery Platforms | Dec 2025 | Series A | $125M | North America | RA Capital; Enavate Sciences; Abiogen; Janus Henderson; Arkin Bio; others |
| Aeovian Pharmaceuticals | Precision therapeutics modulating mTORC1 biology | Therapeutics Discovery Platforms | Dec 2025 | Series B | $55M | North America | Not detailed in source summary |
| Atavistik Bio | Therapeutics discovered through systematic study of allosteric regulation | Therapeutics Discovery Platforms | Dec 2025 | Series B | $120M | North America | Nextech Invest; The Column Group; Lux Capital; Regeneron Ventures |
| Syremis Therapeutics | Next-generation neuropsychiatric therapeutics | Therapeutics Discovery Platforms | Dec 2025 | Series A | $165M | North America | Dexcel Pharma; Third Rock; Bain Capital Life Sciences; GV; QVT; Pictet |
| Mendra | AI-enabled rare-disease biotechnology company acquiring and developing therapeutic candidates | Therapeutics Discovery Platforms | Jan 2026 | Series A | $82M | North America | OrbiMed; 8VC; 5AM Ventures; Lux Capital; Wing VC |
| Corxel Pharmaceuticals | Metabolic therapies including an oral GLP-1 receptor agonist | Therapeutics Discovery Platforms | Jan 2026 | Series D+ | $287M | Asia-Pacific | SR One; TCGX; RA Capital; HBM; SymBiosis; Adage; Invus; RTW; others |
| TRexBio | Regulatory-T-cell-focused therapeutics for autoimmune and inflammatory diseases | Therapeutics Discovery Platforms | Jan 2026 | Unknown | $50M | North America | Janus Henderson; Balyasny; Alexandria; Eli Lilly; JJDC; Pfizer Ventures; Polaris; others |
| Breakthru Medicine | Molecular-glue and ADC-payload drug discovery | Therapeutics Discovery Platforms | Jan 2026 | Series A | $60M | North America | Not detailed in source summary |
| Third Arc Bio | Multifunctional antibody medicines | Therapeutics Discovery Platforms | Feb 2026 | Series A | $52M | North America | Andreessen Horowitz; Omega; Goldman Sachs Alternatives; BVF; T. Rowe Price accounts; others |
| Slate Medicines | Next-generation biologic therapies for migraine | Therapeutics Discovery Platforms | Feb 2026 | Series A | $130M | North America | RA Capital; Forbion; Foresite; unnamed biotech investor |
| BreezeBio | mRNA-mediated immune-tolerance therapeutics | Therapeutics Discovery Platforms | Feb 2026 | Series B | $60M | North America | Not detailed in source summary |
| Atrium Therapeutics | Precision siRNA medicines for inherited cardiovascular disease | Therapeutics Discovery Platforms | Feb 2026 | Unknown | $270M | North America | Not detailed in source summary |
| QL Biopharm | Metabolic therapeutics including long-acting GLP-1 medicines | Therapeutics Discovery Platforms | Mar 2026 | Series C | $72.9M | Asia-Pacific | OrbiMed; Qiming; Five Sources; Xingze; Huagai; Taifu; BlueRun; Taiyu |
| Prolium Bioscience | T-cell-engaging biologics for severe autoimmune disease | Therapeutics Discovery Platforms | Mar 2026 | Series A | $50M | North America | RTW Investments |
| Gilgamesh Pharma | Neuropsychiatric therapeutics and an associated discovery platform | Therapeutics Discovery Platforms | Mar 2026 | Series A | $60M | North America | Satori Neuro; Prime Movers Lab; institutional investors |
| Oncomatryx | Tumor-microenvironment-targeting antibody-drug conjugates | Therapeutics Discovery Platforms | Mar 2026 | Series B | $67M | Europe | Not detailed in source summary |
| Ambrosia Biosciences | Oral small-molecule metabolic therapeutics | Therapeutics Discovery Platforms | Mar 2026 | Series B | $100M | North America | Blue Owl Healthcare Opportunities; Redmile; Deep Track; BVF; Janus Henderson; Samsara |
| Neomorph | Molecular-glue degraders for previously undruggable targets | Therapeutics Discovery Platforms | Apr 2026 | Series B | $100M | North America | Deerfield; Regeneron Ventures; Longwood; Alexandria Venture Investments; others |
| Beeline Medicines | Precision therapeutics for autoimmune and inflammatory disease | Therapeutics Discovery Platforms | Apr 2026 | Series A | $300M | North America | Bain Capital; others |
| Terremoto Biosciences | Covalent-medicine discovery platform developing precision oncology therapeutics | Therapeutics Discovery Platforms | Apr 2026 | Series C | $108M | North America | RA Capital; Deep Track; Osage University Partners; BeOne; OrbiMed; Third Rock; Novo Holdings; Cormorant |
| Storm Therapeutics | RNA-epigenetic medicines targeting RNA-modifying enzymes | Therapeutics Discovery Platforms | Apr 2026 | Series C | $56M | Europe | M Ventures; Pfizer Ventures; Taiho Ventures; IP Group; UTokyo Innovation Platform; Fast Track Initiative |
| Coultreon Biopharma | Precision therapeutics for immune disease | Therapeutics Discovery Platforms | Apr 2026 | Series A | $125M | Europe | Sofinnova; Forbion; Novo Holdings; Galapagos; Regeneron Ventures; Balyasny; Samsara; others |
| Cytospire Therapeutics | Gamma-delta-T-cell-engaging cancer therapeutics | Therapeutics Discovery Platforms | May 2026 | Series A | $83M | Europe | 4BIO; Servier Ventures; British Business Bank; Sound Bioventures; Abingworth; LifeArc; others |
| Isomorphic Labs | AI-native drug discovery company designing therapeutic molecules | Therapeutics Discovery Platforms | May 2026 | Series B | $2,100M | Europe | Thrive Capital; Alphabet; GV; MGX; Temasek; CapitalG; UK Sovereign AI Fund |
| Create Medicines | In-vivo CAR-T and related therapeutic platforms for autoimmune disease and cancer | Cell Therapy Developers | May 2026 | Series B | $122M | North America | Newpath; ARCH; Hatteras Venture Partners; Alexandria Venture Investments |
| Accro Bioscience | Precision immunology therapeutics | Therapeutics Discovery Platforms | May 2026 | Series C | $50M | Asia-Pacific | OrbiMed; TCG Crossover; LAV; Cenova; Shenzhen Capital; Oriza |
| NewLimit | Epigenetic-reprogramming medicines targeting age-related disease | Therapeutics Discovery Platforms | Jun 2026 | Series C | $435M | North America | Founders Fund; Thrive; Greenoaks; Kleiner Perkins; Eli Lilly Ventures; others |
| Ona Therapeutics | Novel antibody-drug conjugates | Therapeutics Discovery Platforms | Jun 2026 | Series B | $86.6M | Europe | Columbus Venture Partners; Mérieux Equity Partners; Korys; Alta Life Sciences; Asabys; Bpifrance; others |
| City Therapeutics | Next-generation RNA-interference medicines | Therapeutics Discovery Platforms | Jun 2026 | Series B | $99.5M | North America | Viking Global; Sofinnova Investments; Casdin; ARCH; Fidelity; Invus; Regeneron Ventures; others |
| Memento Medicines | Bispecific ophthalmic biologics | Therapeutics Discovery Platforms | Jun 2026 | Series A | $93M | North America | Forbion; RA Capital; Avego; Sanofi Ventures; Samsara BioCapital |
| Nura Bio | Neuroprotective therapeutics targeting axon-degeneration biology | Therapeutics Discovery Platforms | Jun 2026 | Series B | $73.8M | North America | The Column Group; Euclidean Capital; Samsara; Sanofi Ventures |
| Osanni Bio | Therapeutics across ophthalmology, cardiovascular disease and oncology | Therapeutics Discovery Platforms | Jun 2026 | Series B | $190M | North America | Patient Square Capital; Horowitz Group; Invus Opportunities; Retinal Degeneration Fund |
| RQ Bio | Antibody discovery and respiratory antiviral biotechnology | Therapeutics Discovery Platforms | Jun 2026 | Series A | $115M | Europe | Frazier Life Sciences; EQT Life Sciences; Forbion; Monograph; Wellington; LifeArc; others |
| Ollin Biosciences | Ophthalmic biologics developer | Therapeutics Discovery Platforms | Jun 2026 | Series B | $330M | North America | TCGX; ARCH; a16z Bio+Health; Blackstone; Commodore; CPP Investments; RA Capital; others |
| Oblenio Bio | Trispecific T-cell engagers for severe autoimmune disease | Therapeutics Discovery Platforms | Jun 2026 | Series B | $62M | North America | Pfizer Ventures; Deep Track; GV; Aditum Bio |
| Lycia Therapeutics | Extracellular targeted-protein-degradation medicines using LYTAC technology | Therapeutics Discovery Platforms | Jun 2026 | Series D+ | $75M | North America | Janus Henderson; Balyasny; Adage; HBM; OrbiMed; Eli Lilly; Franklin Templeton; others |
| Crystalys Therapeutics | Gout biotechnology company advancing dotinurad through registration-directed trials | Therapeutics Discovery Platforms | Jul 2026 | Series B | $130M | North America | Frazier Life Sciences; Wellington; HBM; Soleus; Cormorant; Novo Holdings; SR One; others |
| Ratio Therapeutics | Targeted radiopharmaceutical oncology biotechnology company | Therapeutics Discovery Platforms | Jul 2026 | Series C | $70M | North America | Duquesne Family Office; Bristol Myers Squibb; Catalio; Eli Lilly; Wasatch |
| Epicrispr Biotechnologies | Epigenetic gene-regulation therapies using CRISPR-derived technology | Gene Editing Companies | Aug 2026 | Series C | $90M | North America | Octagon; Janus Henderson; Fidelity; Cormorant; Duquesne; Sanofi Ventures; others |
| Vaderis Therapeutics | AKT inhibition therapy for hereditary hemorrhagic telangiectasia | Therapeutics Discovery Platforms | Aug 2026 | Series B | $152M | Europe | Goldman Sachs Alternatives; TCGX; Omega; EQT Life Sciences; Perceptive; Kalehua; Medicxi; Droia |
| InduPro | Bispecific antibody-drug conjugates using tumor-proximity biology | Therapeutics Discovery Platforms | Aug 2026 | Series B | $77M | North America | The Column Group; Vida; MRL Ventures Fund; Emerson Collective; Euclidean; Sanofi; Eli Lilly; others |
| Abcuro | T-cell-targeting biologics for autoimmune disease | Therapeutics Discovery Platforms | Aug 2026 | Series D+ | $66M | North America | New Leaf; Bain Capital Life Sciences; Samsara; Redmile; RA Capital; Sanofi Ventures; Foresite; NEA; others |
| AusperBio | Oligonucleotide medicines led by an antisense therapy for chronic hepatitis B | Therapeutics Discovery Platforms | Aug 2026 | Series C | $120M | North America | RA Capital; HanKang; Sherpa; InnoPinnacle; Qiming; YuanBio; CDH Investments |

In our biotechnology market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this biotechnology funding tracker from publicly disclosed equity financings announced from August 2025 through September 2, 2026. A company counts as pure-play when more than 80% of its activity is dedicated to biotechnology products or services within the defined scope: biopharma R&D and therapeutics, molecular diagnostics, or core life-science research technologies.
We applied four core filters. First, we only included equity financing, excluding debt, grants, acquisitions, commercial commitments and other non-equity capital. Second, the minimum eligible disclosed financing is $300K. Third, we retained only companies passing the more-than-80% biotechnology pure-play test. Fourth, each financing had to be supported by a direct company announcement, press release or authoritative industry or tier-1 publication.
The clean statistical table contains 77 exact, period-specific financings across 75 unique companies and approximately $11.75B of disclosed capital. Several additional announcements were separated from this clean sample because the headline amount combined historical closes, several financing stages, contingent future capital or an unspecified amount above a lower bound.
Examples include Addition Therapeutics, where the reported $100M described cumulative financing; Vivacta Biotechnology, reported only as $50M+; Serapha Bio, where $92M of a $230M headline was contingent on a transaction; and Ethyreal Bio, where $101M combined Series A and Series B financing. SEED Therapeutics is another important accounting example because only $6M of its $30M headline was actually closed during the study period.
The largest coverage limitation is more fundamental. The strongest systematic biotechnology fundraising tracker used for the research focuses on financings above approximately $50M, while the requested minimum is $300K. The resulting sample is therefore suitable for analyzing large-round capital allocation but cannot honestly establish the full biotechnology market's total deal count, true median round size, small-round distribution or exhaustive category shares.
How active has fundraising been in the biotechnology market?
As of September 2026, fundraising in the biotechnology market has been extremely active at the large-round end over the 12-month analytical period. The clean verified sample contains 77 exact financings totaling approximately $11.75B, raised by 75 unique biotechnology companies.
That total should be interpreted as a floor rather than the total market. The strongest systematic source used in the research is optimized toward financings above $50M, leaving much of the $300K-to-$50M biotechnology market outside systematic coverage.
The scale of visible financing is nevertheless substantial. The verified sample has an average financing size of approximately $153M and a median of $101M, showing how strongly large institutional rounds dominate the observable dataset.
Industry-wide monthly sources confirm that the missing tail matters. January 2026 alone contained 31 significant private biotechnology financings according to a broader industry review, showing that the 77-row clean table cannot represent every qualifying transaction globally.
For a deeper view of financing activity, companies and market structure, see our full biotechnology market report.
How concentrated has fundraising been in the biotechnology market?
As of September 2026, fundraising in the biotechnology market is meaningfully concentrated, but the 12-month verified sample is not completely dependent on one company. The largest financing represents 17.9% of captured capital, while the top 3 rounds represent 26.7% and the top 5 represent 32.6%.
Isomorphic Labs is the largest outlier at $2.1B. Kailera Therapeutics follows at $600M, NewLimit at $435M, Tubulis at $361M and Ollin Biosciences at $330M.
The top 10 financings collectively account for approximately 44.3% of the $11.75B clean sample. This means more than half of captured capital still sits outside the ten largest rounds, despite the presence of a $2.1B outlier.
Concentration therefore matters most when interpreting short-term category or regional totals. One financing can materially alter an apparent trend even when the broader biotechnology funding base remains diversified across many companies.
How much of the biotechnology funding signal is driven by outliers?
As of September 2026, outliers materially influence the biotechnology funding signal over the 12-month analytical period. Isomorphic Labs alone contributes $2.1B, equivalent to 17.9% of all capital in the 77-deal clean sample.
The effect is particularly important for Europe and Therapeutics Discovery Platforms because Isomorphic Labs belongs to both. Any capital-share analysis of either group should therefore be shown both with and without the $2.1B financing.
Several additional financings are individually capable of moving aggregate statistics: Kailera raised $600M, NewLimit $435M, Tubulis $361M, Ollin Biosciences $330M and Kriya Therapeutics $313M.
The practical reading rule is simple: biotechnology dollar totals should always be checked against their top contributors. We examine those concentration effects in more detail in our biotechnology funding analysis.

This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
Is the biotechnology market broad with many targets, or narrow with few fundable companies?
As of September 2026, the biotechnology market itself is broad, but the 12-month verified large-round sample is narrow in what it captures. The clean dataset contains 75 unique companies, yet 69 of its 77 financings are classified as Therapeutics Discovery Platforms.
That concentration does not mean biotechnology lacks diagnostics, synthetic biology or bioprocessing companies. It means the systematic source base is more likely to capture therapeutics companies because their financing requirements frequently exceed $50M.
Only two companies appear twice in the clean exact-value sample: Crystalys Therapeutics and Ollin Biosciences. Most companies therefore contribute one observed financing even though the market contains a large number of separate institutional targets.
The correct conclusion is that the large-round opportunity set is broad by company count but narrow by business model. A full $300K+ census would almost certainly broaden the category mix substantially.
Is biotechnology mostly an early-stage formation market or a late-stage scaling market?
As of September 2026, the biotechnology market cannot be described cleanly as either early-stage formation or late-stage scaling based on financing labels alone. Over the 12-month sample, Series B contributes the most capital at approximately $5.51B, while Series A still represents 23 financings and $2.40B.
Series C contributes 12 financings and approximately $1.82B, while Series D+ contributes five financings and $706M. Nine financings totaling about $1.18B have an Unknown stage.
The important complication is that biotechnology financing stage often diverges from scientific maturity. Crystalys raised a $205M Series A around an asset already approved in Asia, while Expedition and other large Series A companies were built around advanced or externally sourced programs.
Corporate financing stage should therefore be analyzed separately from preclinical, Phase 1, Phase 2 or registration-stage asset maturity. For more on this distinction, see our report on biotechnology companies and financing stages.
Which categories attract the most investor attention in biotechnology?
As of September 2026, Therapeutics Discovery Platforms attract by far the most investor attention in the 12-month verified biotechnology sample. They account for 69 of 77 clean financings and approximately $10.69B of the $11.75B captured.
Gene Editing Companies account for four clean financings totaling $650M, led by Kriya Therapeutics at $313M. Cell Therapy Developers also account for four financings, totaling $412M.
Diagnostic Technology Firms, Synthetic Biology Platforms and Bioprocessing Tool Providers do not appear in the clean large-round sample. That absence should not be interpreted as no funding activity because smaller typical check sizes are precisely what a $50M-heavy source base is least likely to capture.
The category ranking is therefore useful for understanding where very large institutional checks are going, but not for measuring the full formation rate of biotechnology companies.

This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Which categories attract disproportionately large checks in the biotechnology market?
As of September 2026, Therapeutics Discovery Platforms attract the largest checks in absolute terms across the 12-month verified biotechnology sample. Their 69 clean financings total approximately $10.69B, or more than 90% of captured capital.
The category includes several fundamentally different financing architectures: AI-native discovery at Isomorphic Labs, metabolic medicines at Kailera, epigenetic reprogramming at NewLimit, ADC technology at Tubulis and clinical-stage ophthalmology at Ollin.
Gene Editing Companies have fewer observations but still attract large institutional rounds. Four clean deals total $650M, including Kriya at $313M, AAVantgarde Bio at $141M, Profluent at $106M and Epicrispr at $90M.
Cell Therapy Developers show a more selective financing profile, with four clean transactions totaling $412M. The strongest rounds generally combine modality differentiation with clinical evidence, manufacturing progress or a clearer deployment path.
Which geographies matter most for fundraising in the biotechnology market?
As of September 2026, North America matters most for biotechnology fundraising in the 12-month verified sample. The region contributes 58 of 77 clean financings and approximately $7.44B of the $11.75B captured.
Europe contributes 14 clean financings totaling approximately $3.72B. That dollar share is heavily influenced by Isomorphic Labs' $2.1B Series B, so Europe's observed capital weight is much larger than its deal-count share.
Asia-Pacific contributes five clean financings and approximately $593M. Minghui Pharmaceutical, Arnatar Therapeutics, Corxel Pharmaceuticals, QL Biopharm and Accro Bioscience make up the exact-value Asia-Pacific sample.
The large-round evidence therefore supports clear North American leadership but not an exact global deal-formation share. For a broader geographic view, explore our biotechnology market report by region.
Is the biotechnology opportunity set broad or concentrated in one hub?
As of September 2026, the biotechnology opportunity set is geographically concentrated in North America at the large-round level, but it is not a one-hub market. Over the 12-month sample, North America accounts for 58 deals, Europe for 14 and Asia-Pacific for five.
Europe demonstrates that lower deal density does not prevent very large individual financings. Isomorphic Labs raised $2.1B, Tubulis $361M, Hemab Therapeutics $157M and Vaderis Therapeutics $152M.
Asia-Pacific is more lightly represented in this large-round sample, yet Corxel raised $287M and Minghui raised $131M. Those transactions show that global institutional capital remains available for differentiated programs with advanced or globally relevant assets.
No clean exact-value deal in the supplied sample is classified in Latin America, the Middle East or Africa. Given the data-coverage limitation, that should be read as absence from this verified large-round dataset rather than proof of zero biotechnology financing.

This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
Is biotechnology a market of small experiments or scaled financings?
As of September 2026, the visible biotechnology dataset is overwhelmingly a market of scaled financings over the 12-month analytical period. The median clean round is $101M and the average is approximately $153M.
Ten of the 77 clean financings are $200M or larger. Another 32 fall from $100M to below $200M, while 35 fall from $50M to below $100M.
There are no clean transactions below $50M in this particular statistical sample. That is a data-coverage effect rather than evidence that small biotechnology rounds disappeared, because the principal systematic tracker explicitly concentrates on large financings.
This makes the sample excellent for studying institutional capital concentration but unsuitable for estimating the real median biotechnology round. A deeper discussion of financing scale is available in our full biotechnology market deck.
Who are the investors that appear the most in biotechnology fundraising?
As of September 2026, specialist life-science investors dominate repeat participation in the biotechnology market over the 12-month analytical period. RA Capital, OrbiMed, Sofinnova, Novo Holdings, Janus Henderson, Alexandria Venture Investments, Forbion and several other institutional investors recur across multiple financings.
RA Capital appears across metabolic disease, ophthalmology, antibodies, genetic medicine and immunology. OrbiMed similarly spans multiple therapeutic areas rather than representing a concentrated bet on one modality.
Strategic pharmaceutical investors also recur repeatedly. Eli Lilly, Sanofi, Pfizer, Regeneron, Bristol Myers Squibb and other industry participants invest upstream alongside specialist financial investors, effectively using venture syndicates as external portfolio-option mechanisms.
Syndicate composition can therefore add information beyond round size. Multiple credible specialists or competing pharmaceutical companies in the same financing may offer stronger external validation than a large amount supplied by a narrow sponsor base.
Individual investor check sizes are rarely disclosed, so participation frequency is more reliable than assigning each investor the full value of every round it joined. Round size measures company financing, not the amount contributed by each named investor.

This chart, featured in our biotechnology market deck, breaks down revenue across customer segments in the biotechnology market
Fierce Biotech (2025 fundraising tracker), Fierce Biotech (2026 fundraising tracker), Labiotech.eu (January 2026 biotechnology funding), Labiotech.eu (November 2025 biotechnology funding), GlobeNewswire (SEED Therapeutics), GlobeNewswire (Azalea Therapeutics), Cytotheryx (financing update)
Related blog posts
- What are the key fundraising trends in the biotechnology market?
- How funding activity has changed in the biotechnology market
- The startups that have raised the most funding in the biotechnology market
- The latest funding news in the biotechnology market
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.